Docket No. | Op. Below | Argument | Opinion | Vote | Author | Term |
---|---|---|---|---|---|---|
09-1156 | 9th Cir. | Jan 10, 2011 | Mar 22, 2011 | 9-0 | Sotomayor | OT 2010 |
Holding: The plaintiffs have stated a claim for securities fraud under § 10(b) of the Securities and Exchange Act and SEC Rule 10b-5 based on a pharmaceutical company's failure to disclose reports of adverse events associated with a product, even if the reports do not disclose a statistically significant number of adverse events.
Plain English Holding: A drug company’s failure to make public reports of adverse drug reactions can constitute securities fraud, even if the number of adverse reactions is not statistically significant.
Judgment: Affirmed., 9-0, in an opinion by Justice Sotomayor on March 22, 2011.